GREY:ATBPF - Post by User
Comment by
MrMugsyon Jul 27, 2022 2:58pm
186 Views
Post# 34854603
RE:New indications IP
RE:New indications IPCorrect.
Looks like it is also know as ATB-344 or an H2S releasing Indomethacin product.
ATB-344 was initially intended for gout and the market size was about $500M (2013).
For the past 2 years we've been waiting for word of a respiratory/COVID drug - guessing 344 is the winner over Regeneron and ATB-429 (if I recall from the patent).
Also - don't take my word for it as I don't know my chemistry - but - it does look like new H2S chemistry.
I see an N-thiocarboxy design with minimal acute in vitro toxicity observed in multiple cell lines while longer-term toxicity in cancer cells (if related). Tuning the H2S release rate might be easier with this design.
Will see ... if they ever update us.
Then again - I think they owe us a lot of other things before we get any information on this one. All in my opinion.